- Poster presentation
- Open Access
Immune impairment and adaptive response in relation to antiretroviral therapy of HIV-infection
© Kaminskiy and Pronin; licensee BioMed Central Ltd. 2010
- Published: 8 November 2010
- Viral Load
- Immune Reconstitution
- Virus Infected Cell
- Late Presenter
- Progressive Group
In Moscow Regional HIV Living Cohort we have recently defined the groups with progressive HIV infection and those with temporary and permanently no progressive disease. The aim of the study was to find major features of progressive HIV infection in relation to antiretroviral treatment.
In the study 615 progressors were compared with 1311 and 345 temporary and permanently non progressors. Additionally 208 late presenters (with CD4 counts less than 100 cells/mm3) were compared with the sample from the whole population of people leaving with HIV (2271 patient). In blood specimens HIV virus load (PCR m2000rt Abbott, 'RealTime HIV-1') and major subpopulation of T-lymphocytes were analyzed (flow cytometer BD FACSCount, sets ÑD3/CD4/CD8/CD45).
The most distinct feature allocating groups was the response to the elevation of viral load. In the progressive group the number of CD8 cells among individuals decreased with the elevation of viral load. This was due to the T-cell depression including CD8+, CD4+ and CD3+CD4-CD8- T-lymphocytes.
Demonstrated "pathologic process" and "adaptive response" allows better understanding of the HAART efficacy. HAART affects the viral replication thus restoring the proportion between the cytotoxic lymphocytes and virus infected cells. This causes HIV viral load reduction. Immune reconstitution appears to be a host property which depends on the severity of the previous immune impairment.
Viral Load (HIV) (log 10 copies/ml)
CD3+ CD4-CD8- (cells/mm3)
Late Presenters First Group
Late Presenters Second Group
HIV Living Cohort
Depletion of different T-cell branches is the major pathological process in HIV-infection, diagnosis of the level of immune impairment is needed to prescribe appropriate treatment.
- Johnson M, Sabin C, Girardi E: Definition and epidemiology of late presentation in Europe. //Antivir Ther. 2010, 15 (Suppl 1): 3-8. 10.3851/IMP1522.View ArticleGoogle Scholar
- Mollet L, Li TS, Samri A, Tournay C, Tubiana R, Calvez V, Debré P, Katlama C, Autran B: Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups. //J Immunol. 2000, 165 (3): 1692-704.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.